Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the ...

CEO Jay Duker highlighted the progress of DURAVYU, their lead program for treating wet AMD, noting that over 90% of patients have been randomized in the LUGANO trial and over 50% in the LUCIA trial.

IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, ...

In a phase 3 trial Tegoprazan Shows Superior Efficacy and Safety in Treating Esophageal Conditions. It was found that ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical ...

Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 ...

Q2 2025 Management View CEO Mitchell Steiner emphasized Veru’s focus on its obesity program, highlighting the positive Phase 2b clinical trial results for enobosarm. This drug, when combined with ...

The company is currently conducting a pivotal Phase 3 clinical trial named MIRACLE to evaluate the efficacy of Annamycin in combination with cytarabine for AML, with interim results expected in ...

In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 ... Germany 8 Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center ...

guidance on the Phase 3 clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is the company's lead investigational genetically targeted, serotonin-3 receptor antagonist ...